hackint0sh/New-Dataset huggingface dataset:
Statistics: EBL and operative time learning curve is studied. Clinical, pathological, intraoperative risk factors analysis for higher EBL is performed by linear regression modelling. Factors are evaluated independently and jointly. Association between each factor above and post-operative outcomes (i.e. post-op bleeding, need of transfusion and hematuria) is also assessed. conditions: Prostate Cancer conditions: Bleeding conditions: Prostate Adenocarcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 194 type: ACTUAL name: robot-assisted radical prostatectomy measure: Influence of hemoglobin value on haemorrhagic complications measure: Influence of hematocrit value on haemorrhagic complications measure: Influence of platelet count on haemorrhagic complications measure: Influence of blood group on haemorrhagic complications measure: Identification of possibile demographic and surgical predictive factors of haemorrhagic complications sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico city: Milan zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06299033 id: HPS-NP1-101 briefTitle: A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke overallStatus: RECRUITING date: 2023-11-09 date: 2024-08-30 date: 2025-12-30 date: 2024-03-07 date: 2024-03-07 name: Hopstem Biotechnology Inc. class: INDUSTRY briefSummary: The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects with stable chronic ischemic stroke. conditions: Chronic Ischemic Stroke studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 21 type: ESTIMATED name: hNPC01 measure: Incidence of Treatment-Emergent Adverse Events as assessed by physiological parameters during 6 months after intracerebral injection of hNPC01 measure: Incidence of Treatment-Emergent Adverse Events as assessed by physiological parameters during 12 months after intracerebral injection of hNPC01 measure: Number of participants with motor function improvement as assessed by rating scales of Modified Rankin Scale (mRS) during 12 months of treatment measure: Number of participants with motor function improvement as assessed by rating scales of Fugl-Meyer Motor Scale (FMMS) during 12 months of treatment measure: Number of participants with motor function improvement as assessed by rating scales of NIH Stroke Scale (NIHSS) during 12 months of treatment measure: Number of participants with motor function improvement as assessed by rating scales of Barthel Index (BI) during 12 months of treatment sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: XiangYa Hospital status: RECRUITING city: Changsha state: Hunan country: China name: Dan Li role: CONTACT phone: 15074875481 name: Zhiquan Yang, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06299020 id: HLaRabta24 briefTitle: Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2024-04-20 date: 2024-12 date: 2024-03-07 date: 2024-03-07 name: Hopital La Rabta class: OTHER briefSummary: In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting. The present study aimed to assess these risks in a prospective study of 30 subjects with primary adrenal insufficiency. Patients will undergo a clinical examination, blood sampling and continuous glucose monitoring for fourteen days (one week of fasting and one week of non-fasting). conditions: Primary Adrenal Insufficiency conditions: Intermittent Fasting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: intermittent fasting measure: hypoglycemia measure: Dehydration sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299007 id: HYH EC 052-66-01 id: HYH EC 052-66-01 type: OTHER_GRANT domain: Hatyai Hospital Education Center briefTitle: Awareness of Iron Status Evaluation in UGIB acronym: AISE overallStatus: COMPLETED date: 2023-08-01 date: 2023-12-31 date: 2023-12-31 date: 2024-03-07 date: 2024-03-07 name: Hat Yai Medical Education Center class: OTHER briefSummary: BACKGROUND: Data on the awareness of the need to evaluate iron status and IDA prevalence in acute UGIB are limited.
OBJECTIVES: This study aimed to investigate the rate of evaluation of iron status and prevalence of iron deficiency anemia (IDA) and the associated factors in patients with anemia hospitalized for acute upper gastrointestinal bleeding (UGIB). conditions: Upper Gastrointestinal Bleeding studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 867 type: ACTUAL measure: iron status measurement measure: Iron deficiency anemia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hatyai Hospital city: Hat Yai state: Songkhla zip: 90110 country: Thailand lat: 7.00836 lon: 100.47668 hasResults: False
nctId: NCT06298994 id: SBA 23/391 briefTitle: Determination of Body Awareness and the Functional Movement in Patients With COPD overallStatus: NOT_YET_RECRUITING date: 2024-03-08 date: 2025-03-08 date: 2026-03-08 date: 2024-03-07 date: 2024-03-07 name: Hacettepe University class: OTHER briefSummary: The aim of this study is to investigate body awareness and functional movement in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy controls. conditions: Pulmonary Disease, Chronic Obstructive conditions: Postural; Defect conditions: Movement, Abnormal conditions: Pain studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: Evaluation of functional movement measure: Evaluation of Body Awareness measure: Functional exercise capacity measure: Respiratory muscle strength measure: Respiratory muscle endurance measure: Pain Severity measure: Pain threshold measure: Posture measure: Daily living activities measure: Severity of disease measure: Dyspnea measure: Symptoms sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Aynur Demirel city: Ankara zip: 06100 country: Turkey lat: 39.91987 lon: 32.85427 facility: Hacettepe University city: Ankara zip: 06100 country: Turkey name: Aynur Demirel role: CONTACT phone: +905545295057 phoneExt: 178 email: aynur.demirel@hacettepe.edu.tr name: hidaye yamikan role: CONTACT phone: +905349898724 email: hidaye.yamikan@hacettepe.edu.tr name: hidaye yamikan role: SUB_INVESTIGATOR name: cansu akkus role: SUB_INVESTIGATOR lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06298981 id: 2301 briefTitle: Pulse Rate and Breathing Rate Accuracy overallStatus: RECRUITING date: 2024-02-12 date: 2024-06-30 date: 2024-06-30 date: 2024-03-07 date: 2024-03-22 name: Nuralogix Corporation class: INDUSTRY briefSummary: The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis. conditions: Pulse Rate and Breathing Rate studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED name: noninvasive and investigational NuraLogix AMC-SDK measure: Breathing rate accuracy validation measure: Pulse rate accuracy validation measure: Pulse rate simulation sex: ALL minimumAge: 18 Years maximumAge: 81 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Element Materials Technology status: RECRUITING city: Louisville state: Colorado zip: 80027 country: United States name: Monica Rabanal role: CONTACT lat: 39.97776 lon: -105.13193 hasResults: False
nctId: NCT06298968 id: NFEC-2024-074 briefTitle: Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma overallStatus: RECRUITING date: 2024-02-25 date: 2025-02-25 date: 2027-02-25 date: 2024-03-07 date: 2024-03-07 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma conditions: Intrahepatic Cholangiocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 38 type: ESTIMATED name: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab measure: Objective response rate (ORR) measure: The disease control rate (DCR) measure: Duration of response (DOR) measure: The median progression free survival time (mPFS) measure: The median overall survival time (mOS) measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang Hospital of Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Mengya Zang role: CONTACT phone: 86-20-62787430 email: zangmy@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06298955 id: OMS906-PNH-003 briefTitle: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria overallStatus: RECRUITING date: 2024-02-19 date: 2026-12 date: 2027-04 date: 2024-03-07 date: 2024-03-07 name: Omeros Corporation class: INDUSTRY briefSummary: The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH. conditions: Paroxysmal Nocturnal Hemoglobinuria studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: OMS906 study drug measure: To assess overall safety and tolerability of OMS906 administration at 8-week intervals in PNH patients. measure: To assess efficacy measured by hemoglobin (Hgb). measure: To assess efficacy by transfusion requirements. measure: To assess efficacy by measurement of lactate dehydrogenase (LDH). measure: To assess efficacy by measurement of reticulocyte count. measure: To assess efficacy by measurement of clinical breakthrough hemolysis. measure: To assess population PK Cmax of OMS906. measure: To assess population PK AUC of OMS906. measure: To assess population PK terminal half life of OMS906. measure: To assess PD of OMS906 measure: OMS906 anti-drug antibodies (ADA). measure: Assess the change in Functional Assessment of Chronic Illness Therapy (FACIT) fatigue score. sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Omeros Investigational Site status: NOT_YET_RECRUITING city: Aachen country: Germany lat: 50.77664 lon: 6.08342 facility: Omeros Investigational Site status: NOT_YET_RECRUITING city: Ulm country: Germany lat: 48.39841 lon: 9.99155 facility: Omeros Investigational Site status: RECRUITING city: Lausanne country: Switzerland lat: 46.516 lon: 6.63282 facility: Omeros Investigational Site status: NOT_YET_RECRUITING city: Kyiv country: Ukraine lat: 50.45466 lon: 30.5238 facility: Omeros Investigational Site status: NOT_YET_RECRUITING city: Leeds country: United Kingdom lat: 53.79648 lon: -1.54785 hasResults: False
nctId: NCT06298942 id: fac.med.24.9 briefTitle: Naturally Banded Versus Synthetic Banding of Sleeve Gastrectomy overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-06-15 date: 2025-07-15 date: 2024-03-07 date: 2024-03-07 name: Minia University class: OTHER briefSummary: to compare banding sleeve gastrectomy using silicone ring Versus using natural flap ( round ligament of the liver) conditions: Obesity, Morbid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 250 type: ESTIMATED name: natural band name: silicone band measure: total cost measure: food intolerance measure: %EWL measure: complications rate measure: improvement of comorbidities sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298929 id: 36264PR427/11/23 briefTitle: Medial Rectus Fenestration vs Recession for PAET overallStatus: RECRUITING date: 2023-11-15 date: 2024-09-15 date: 2024-10-15 date: 2024-03-07 date: 2024-03-07 name: Mansoura University class: OTHER name: Tanta University briefSummary: This prospective comparative study aims to compare medial rectus (MR) muscle fenestration and recession in patients with partially accommodative esotropia (PAET). The main question it aims to answer is whether MR fenestration is equally effective as MR recession for PAET.
All patients will receive complete ophthalmic and orthoptic assessment. Patients will be randomly allocated using a random table to one of two groups; Group 1 will receive conventional MR recession, and Group 2 will receive MR fenestration. conditions: Partially Accommodative Esotropia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: medial rectus fenestration name: medial rectus recession measure: Ocular alignment (measured in prism diopters) measure: ocular motility sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Tanta University status: RECRUITING city: Tanta state: Gharbeya country: Egypt name: Heba M Shafeik, MD role: CONTACT phone: +201227440829 email: heba.saeid@med.tanta.edu.eg lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06298916 id: FAPi-1301 briefTitle: 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer acronym: PHANTOM overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-11 date: 2026-04 date: 2024-03-07 date: 2024-03-07 name: Lantheus Medical Imaging class: INDUSTRY briefSummary: This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2). conditions: Metastatic Sarcoma conditions: Esophageal Cancer conditions: Gastric Cancer conditions: Pancreatic Cancer conditions: Colorectal Cancer conditions: Sarcoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Part 1: Metastatic Sarcoma Part 2: Non-metastatic sarcoma or gastrointestinal tract (GIT) cancer (esophageal, gastric, pancreatic, colorectal cancer) primaryPurpose: DIAGNOSTIC masking: NONE count: 32 type: ESTIMATED name: 64Cu-LNTH-1363S measure: Primary Part 1 Biodistribution of 64Cu-LNTH-1363S measure: Primary Part 1 - Optimal dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S measure: Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression measure: Secondary Parts 1 and 2 Safety and Tolerability measure: Secondary Part 1 FAP expression profile of 64Cu-LNTH-1363S in patients with sarcoma measure: Secondary Part 1 and Part 2 Cardiac Safety measure: Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer measure: Exploratory Part 1 and Part 2 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06298903 id: STUDY00002565 briefTitle: Impact of Hip Activation Compared to Hip Plus Balance Training on the Forward-Step-Down Test overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-12 date: 2024-03-25 date: 2024-08 date: 2024-03-07 date: 2024-04-29 name: Louisiana State University Health Sciences Center Shreveport class: OTHER briefSummary: The purpose of this research is to determine the impact of a hip activation home exercise program (HEP) compared to a hip activation + single leg balance HEP on performance of the Forward-Step-Down Test (FSDT) in healthy females. Participants will be assigned to the control (hip activation HEP only) or experimental (hip activation + single leg balance HEP). Following the pre-test data collection, participants will complete their HEP for 8 weeks. They will return to the lab for post-test measurements. conditions: Control of Frontal Plane Biomechanics conditions: Patellofemoral Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The investigator who will analyze the data will be blinded whoMasked: INVESTIGATOR count: 34 type: ACTUAL name: Hip Activation name: Hip activation + Single leg balance measure: Forward-Step-Down Test measure: surface electromyography (sEMG) peak measure: surface electromyography (sEMG) mean measure: Unipedal Stance Test (UPST) measure: Dose-Response sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LSUHSC-Shreveport city: Shreveport state: Louisiana zip: 71103 country: United States lat: 32.52515 lon: -93.75018 hasResults: False
nctId: NCT06298890 id: SASKAT briefTitle: The Pattern of Dry Eye Disease After Cataract Surgery overallStatus: RECRUITING date: 2024-03 date: 2026-05 date: 2027-09 date: 2024-03-07 date: 2024-03-07 name: Lithuanian University of Health Sciences class: OTHER name: Santen Oy briefSummary: This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up. conditions: Dry Eye Disease conditions: Cataract conditions: Ocular Surface Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Artificial tears (sodium hyaluronate 0.2%) measure: Assessment of ocular surface changes following cataract surgery measure: Evaluation of the cornea morphology measure: Evaluation of matrix metalloproteinase-9 (MMP-9) levels in patients' tears measure: Evaluation of tear osmolarity measure: Evaluation of tear cytokine levels measure: Assessment of central corneal sensitivity measure: Evaluation of potential pain biomarkers in patients' saliva measure: Dry Eye Questionnaire-5 (DEQ5) 5-item measure: Ocular surface disease index (OSDI) measure: Visual function (VFQ-25) questionnaire measure: Visual acuity evaluation (LogMAR) sex: ALL minimumAge: 50 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lithuanian University of Health Sciences status: RECRUITING city: Kaunas zip: LT-44307 country: Lithuania name: Reda Zemaitiene role: CONTACT phone: + 370 37 327 201 email: rektoratas@lsmu.lt lat: 54.90272 lon: 23.90961 hasResults: False
nctId: NCT06298877 id: 2023-04696-01 briefTitle: Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer acronym: FOLERO overallStatus: RECRUITING date: 2024-03-11 date: 2029-03-28 date: 2029-03-28 date: 2024-03-07 date: 2024-03-20 name: Sahar Salehi class: OTHER briefSummary: Complete macroscopic surgical resection (CMR) requires extensive surgery and combined with chemotherapy confers best chance of survival in advanced ovarian cancer. During cytoreductive surgery 11% of women require a temporary diverting intestinal stoma.
The FOLERO study is a prospective adequately powered national cohort study with aim to determine if frailty instruments may be used to select patient to surgical treatment. In addition, we test the feasibility of early stoma reversal after index cytoreductive surgery in a small phase I trial and follow our patients Health Related Quality of Life after state of the art surgical treatment. conditions: Ovarian Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 450 type: ESTIMATED name: Frailty and Quality of Life evaluation measure: Overall Survival measure: 1-year mortality measure: Health related quality of life (HRQoL) (QLQ-C30) measure: Health related quality of life (HRQoL) (QLQ-OV28) measure: Health related quality of life (HRQoL) (QLQ-ELD14) measure: Health related quality of life (HRQoL) (EQ-5D-5L) measure: Low anterior resection syndrome (LARS) measure: Postoperative complications measure: Readmissions measure: Length of hospital stay measure: Extent of surgery vs survival measure: Sarcopenia vs post-operative outcome measure: Standard regimen of adjuvant chemotherapy measure: Time interval to adjuvant chemotherapy measure: Total number of hospital days and readmissions within90 days after index surgery measure: Health economics measure: Recurrence or progression free survival sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Karolinska University Hospital status: RECRUITING city: Stockholm state: Solna zip: 171 76 country: Sweden name: Sahar Salehi, MD, Ass Prof role: CONTACT email: sahar.salehi@regionstockholm.se name: Daniel Hunde, MD role: CONTACT email: daniel.hunde@regionstockholm.se name: Daniel Hunde, MD role: SUB_INVESTIGATOR name: Sahar Salehi, MD, Ass Prof role: PRINCIPAL_INVESTIGATOR lat: 59.33258 lon: 18.0649 facility: Sahlgrenska University Hospital and Sahlgrenska Academy status: NOT_YET_RECRUITING city: Gothenburg zip: 41685 country: Sweden name: Pernilla Dahm-Kähler, MD, Prof. role: CONTACT phone: 0313434216 email: pernilla.dahm-kahler@gu.se name: Pernilla Dahm-Kähler, MD, Prof. role: PRINCIPAL_INVESTIGATOR name: Charlotte Palmqvist, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 57.70716 lon: 11.96679 facility: Linköping University Hospital status: RECRUITING city: Linköping zip: 581 85 country: Sweden name: Madelene Wedin, MD, PhD role: CONTACT email: madelene.wedin@regionostergotland.se name: Madelene Wedin, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 58.41086 lon: 15.62157 facility: Skåne University Hospital status: NOT_YET_RECRUITING city: Lund zip: 22185 country: Sweden name: Mihaela Asp, MD, PhD role: CONTACT email: Mihaela.Asp@skane.se name: Mihaela Asp, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Päivi Kannisto, MD, Ass Prof role: SUB_INVESTIGATOR lat: 55.70584 lon: 13.19321 hasResults: False